Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
HCWB
Upturn stock ratingUpturn stock rating

HCW Biologics Inc (HCWB)

Upturn stock ratingUpturn stock rating
$4.5
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: HCWB (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $35

1 Year Target Price $35

Analysts Price Target For last 52 week
$35Target price
Low$3.55
Current$4.5
high$62.4

Analysis of Past Performance

Type Stock
Historic Profit 33.03%
Avg. Invested days 44
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 9.36M USD
Price to earnings Ratio -
1Y Target Price 35
Price to earnings Ratio -
1Y Target Price 35
Volume (30-day avg) 1
Beta 0.83
52 Weeks Range 3.55 - 62.40
Updated Date 06/30/2025
52 Weeks Range 3.55 - 62.40
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -24.8

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -78298.16%

Management Effectiveness

Return on Assets (TTM) -57.2%
Return on Equity (TTM) -27725.96%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 22188390
Price to Sales(TTM) 6.47
Enterprise Value 22188390
Price to Sales(TTM) 6.47
Enterprise Value to Revenue 15.35
Enterprise Value to EBITDA -3.63
Shares Outstanding 2079180
Shares Floating 731958
Shares Outstanding 2079180
Shares Floating 731958
Percent Insiders 29.8
Percent Institutions 1.47

Analyst Ratings

Rating 1
Target Price 35
Buy 1
Strong Buy -
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

HCW Biologics Inc

stock logo

Company Overview

overview logo History and Background

HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing innovative immunotherapies to address unmet needs in cancer, age-related diseases, and autoimmune conditions. Founded in 2018, the company's core technology is based on its TOBIu2122 (Tissue microenvironment-resident Onco-immunotherapies) platform.

business area logo Core Business Areas

  • Drug Discovery & Development: HCW Biologics focuses on discovering and developing novel biologic therapeutics using its TOBIu2122 platform. This includes identifying therapeutic targets, designing drug candidates, and conducting preclinical and clinical studies.
  • TOBIu2122 Platform Technology: The company's proprietary TOBIu2122 platform is at the core of its drug development efforts. This platform allows for the development of novel biologics that target specific disease microenvironments.
  • Clinical Trials: HCW Biologics conducts clinical trials to evaluate the safety and efficacy of its drug candidates in human patients. These trials are essential for obtaining regulatory approval and bringing new therapies to market.

leadership logo Leadership and Structure

Hing C. Wong is the Founder and CEO. The company has a research and development team focusing on drug discovery and clinical development.

Top Products and Market Share

overview logo Key Offerings

  • HCW9218: Lead drug candidate, a TOBIu2122 molecule designed to target age-related diseases and certain cancers. Currently in Phase 1 clinical trials. Market share is currently 0, as it's still in clinical trials. Competitors include companies developing therapies for similar indications (e.g., anti-aging and cancer immunotherapies).
  • HCW7202: Another TOBIu2122 molecule targeting cancer. Preclinical development is ongoing. Market share is currently 0. Competitors are cancer therapeutics developers.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive and dynamic, with significant investments in research and development. The immunotherapy market, in particular, is experiencing rapid growth due to the increasing prevalence of cancer and autoimmune diseases.

Positioning

HCW Biologics is positioned as an innovative immunotherapy company leveraging its TOBIu2122 platform. Its competitive advantage lies in its novel approach to targeting disease microenvironments.

Total Addressable Market (TAM)

The total addressable market for immunotherapies is substantial and growing. The immunotherapy market is projected to reach hundreds of billions of dollars in the coming years. HCW Biologics aims to capture a portion of this market with its pipeline of TOBIu2122-based therapeutics.

Upturn SWOT Analysis

Strengths

  • Proprietary TOBIu2122 platform technology
  • Innovative approach to immunotherapy
  • Strong scientific leadership
  • Targeting unmet medical needs

Weaknesses

  • Early-stage development pipeline
  • Reliance on funding for clinical trials
  • Small company size compared to established competitors

Opportunities

  • Positive clinical trial results
  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Growing demand for immunotherapies

Threats

  • Clinical trial failures
  • Competition from established immunotherapy companies
  • Regulatory hurdles
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • MRNA
  • PFE
  • BMY

Competitive Landscape

HCW Biologics faces competition from large pharmaceutical companies with established immunotherapy platforms. HCW's advantage lies in its TOBIu2122 technology's potential to provide more targeted and effective therapies.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by preclinical and early-stage clinical development.

Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and commercialization of its therapies.

Recent Initiatives: Focusing on advancing HCW9218 through Phase 1 clinical trials and expanding the TOBI platform.

Summary

HCW Biologics is an early-stage biopharmaceutical company with a novel immunotherapy platform. The company's success hinges on positive clinical trial results for its lead drug candidates. The company faces stiff competition in the immunotherapy market but has the potential to disrupt the field with its innovative TOBIu2122 technology. Securing partnerships and additional funding will be important.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • HCW Biologics Inc. Website
  • Sec Filings
  • Analyst Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Investment decisions should be based on thorough due diligence and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About HCW Biologics Inc

Exchange NASDAQ
Headquaters Miramar, FL, United States
IPO Launch date 2021-07-20
Founder, CEO, Director & Secretary Dr. Hing C. Wong Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 36
Full time employees 36

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201 and HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer. The company has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.